q-bio.QMNov 18, 2026

STORM: A Lightweight Structure-Free Model for Binding Affinity Prediction

Authors: Ayush Pandit, Rohan V. Koodli, Wei Deng, Roxana Daneshjou, Ron O. Dror

Organizations: Stanford University

Abstract

Accurately predicting a small molecule's binding affinity to a protein, a critical task in drug discovery, remains challenging. Physics-based approaches like free-energy perturbation (FEP) have very high computational costs and require expert setup. Recent machine learning--based cofolding models have reported accuracy approaching that of FEP---and at least one of them, Boltz-2, has already been widely adopted for affinity prediction---but they remain expensive for large computational screens and even more expensive for retraining on newly collected experimental data. To address these challenges, we introduce STORM: Similarity Transfer from Observed Reference Molecules. STORM is a fast, simple machine learning model that ensembles many small model fusions of diverse protein and molecule representations for binding affinity prediction. Trained on the same data, STORM matches or exceeds the accuracy of Boltz-2 on multiple evaluation datasets, while delivering a speed improvement of over five orders of magnitude for both inference and training. Our results also suggest opportunities to substantially improve affinity prediction accuracy by integrating historical experimental affinity data with structural and biophysical information.

Figures & tables

Appendix figures & tables15 assets

Supplementary material from the paper’s appendix.

Appendix

Explore similar work

Jul 21, 2026

DBMol: Design of High-Affinity, Target-Specific Small Molecules through Structure Prediction Models

Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeutics. Recent breakthroughs in structure prediction, such as AlphaFold-3 and Boltz-2, enable accurate biomolecular interaction prediction and show promise as foundation models for downstream tasks, including binding affinity prediction. We propose to leverage these models and introduce DBMol, a new structure predictor-guided framework for de novo small molecule design. DBMol formulates an alternating optimization and projection process. In the optimization stage, DBMol starts from an initial molecule and uses gradient-based optimization to improve pocket-specific interactions and predicted binding affinity using a structure prediction model. In the projection stage, a flow-matching model maps the optimized molecular graph to discrete and chemically valid molecules. Experiments show that DBMol effectively optimizes the Boltz-2 affinity proxy and generates molecules with strong predicted affinity and specificity under Boltz-2 evaluation. To reduce self-confirmation bias, we further evaluate generated molecules using held-out metrics, including AF3-based evaluation. DBMol substantially improves pocket coverage while maintaining molecular diversity over unconditional generation, and is competitive under held-out metrics despite the absence of reference-ligand supervision. These results support the promise of structure prediction models as effective optimization signals for de novo molecular design.
Nov 3, 2026

Molecular Prior Networks

Predicting affinity between small molecules and their protein targets remains one of the central problems in drug discovery. Due to the substantial cost of wet-lab experiments, machine learning models of drug-target affinity are usually trained on relatively small datasets, ranging from tens to hundreds of molecules. Given the inherent difficulty of generalization between different targets and chemical series, existing datasets of protein-ligand affinities are typically not used for new projects. At the same time, tabular foundation models, including Prior-data Fitted Networks, have recently shown how transformers can be used to solve machine learning problems in a single forward pass of the network, after being trained over a large corpus of, typically, synthetic datasets. Inspired by that line of work, we propose a novel affinity modelling approach, in which the labels of the query molecules are predicted from the labelled support molecules in a single forward pass of a transformer model. The model is trained on thousands of existing affinity datasets, enabling it to capture the general patterns of molecular activity across different targets, chemical series and dataset sizes. For the smallest support sets, our model matches the state of the art on the regression variant of the FS-Mol benchmark, while being faster than existing methods, thanks to the lack of task-specific training. A comparison against a reduced variant of our architecture, which amounts to kernel regression in a meta-learned feature space, shows that the predictive performance of the transformer model is only partially explained by simple molecular similarity.
Mar 2, 2026

On the Reliability of AI Methods in Drug Discovery: Evaluation of Boltz-2 for Structure and Binding Affinity Prediction

Despite continuing hype about the role of AI in drug discovery, no "AI-discovered drugs" have so far received regulatory approval. Here we assess one of the latest AI based tools in this domain. The ability to rapidly predict protein-ligand structures and binding affinities is pivotal for accelerating drug discovery. Boltz-2, a recently developed biomolecular foundation model, aims to bridge the gap between AI efficiency and physics-based precision through a joint "co-folding" approach. In this study, we provide an extensive evaluation of Boltz-2 using two large-scale datasets: 16,780 compounds for 3CLPro and 21,702 compounds for TNKS2. We compare Boltz-2 predicted structures with traditional docking and binding affinities with binding free energies derived from the physics-based ESMACS protocol. Structural analysis reveals significant global RMSD variations, indicating that Boltz-2 predicts multiple protein conformations and ligand binding positions rather than a single converged pose. Energetic evaluations exhibit only weak to moderate correlations across the global datasets. Furthermore, a focused analysis of the top 100 compounds yields no significant correlation between the Boltz-2 predictions and the binding free energies from fine-grained ESMACS, alongside observed saturation difference in ligand structures. Our results show that while Boltz-2 offers substantial speed for initial screening, it lacks the energetic resolution required for lead identification. These findings highlight the necessity of employing physics-based methods for the reliability and refinement of AI-derived models.